• А.P. Burlaka R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • S.V. Virko V.E. Lashkaryov Institute of Semiconductor Physics
  • V.M. Grygorenko Institute of Urology of the National Academy of Medical Sciences of Ukraine
  • O.A. Samoylenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • A.V. Verbinenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • V.O. Shlyakhovenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology



intraepithelial neoplasia, NO-synthase, prostate cancer, RNase


Aim: To assess the inducible NO-synthase activity and the total RNase activity in tissue samples and blood neutrophils of the patients with prostate intraepithelial neoplasia (PIN) and prostate cancer (PCa) of different stages. Materials and Methods: NO level was measured in tumor tissue and neutrophils of patients with PIN and PCa of different stages by electron paramagnetic resonance using the spin traps technology. RNase activity in tumor tissue of patients with PIN and PCa was measured by the method of zymography. Results: We have found that NO levels in prostate tumor tissue were significantly higher than in the PIN and increased along with the disease progression. Analysis of NO level in neutrophils of the PCa patients demonstrated that the values were not dispersed and did not depend on the stage of disease. NO level in neutrophils of the PCa patients increased manifold as compared with that in healthy donors. At the same time, the RNase activity in the prostate tumor tissue gradually decreased with PCa progression. Conclusion: Activities of inducible NO-synthase and RNases change significantly with progression of PCa.


Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765–81.

Soni Y, Softness K, Arora H, Ramasamy R. The yin yang role of nitric oxide in prostate cancer. Am J Mens Health 2020; 14: 1557988320903191.

Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox Biol 2015; 6: 334–43.

Masucci MT, Minopoli M, Carriero MV. Tumour associated neutrophils: their role in tumourigenesis, metastasis, prognosis and therapy. Front Oncol 2019; 9: 1146.

Burlaka AP, Sidorik EP. Redox-dependent signal molecules in mechanisms of tumour process. Kyiv. 2014.

Erlandsson A, Carlsson J, Andersson SO, et al. High inducible nitric oxide synthase in prostate tumor epithelium is associated with lethal prostate cancer. Scand J Urol 2018; 52: 129–33.

Shlyakhovenko VO. Ribonucleases. Possible new approach in cancer therapy. Exp Oncol 2016; 38: 2–8.

Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry 2003; 42: 1805–12.

Shook SJ, Beuten J, Torkko KC, et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res 2007; 13: 5959–64.

Burlaka AP, Ganusevich II, Lukin SN, et al. Superoxide-and NO-dependent mechanisms of the reprogramming of bone marrow cells by tumour cells. Appl Magn Reson 2014; 45: 1261–73.

Burlaka AP, Ganusevich II, Gafurov MR, et al. Electron paramagnetic resonance study of tumor affected bone marrow. Cancer Microenviron 2013; 6: 273–6.

Burlaka AP, Gafurov MR, Iskhakova KB, et al. Electron paramagnetic resonance in the experimental oncology: implementation examples of the conventional approaches. Bionanoscience 2016; 6: 431–6.

Liao W, Ye T, Liu H. Prognostic value of inducible nitric oxide synthase (iNOS) in human cancer: a systematic review and meta-analysis. Biomed Res Int 2019; 2019: 1–9.

Aaltoma SH, Lipponen PK, Kosma VM. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 2001; 21: 3101–6.

Burlaka AP, Sidoryk EP. Radical forms of oxygen and nitric oxide in the tumour process. K: Nauk Dumka, 2006. 228 р. (in Ukrainian).

Galkin A, Higgs A, Moncada S. Nitric oxide and hypo­xia. Essays Biochem 2007; 43: 29–42.

Tan G, Qiu M, Chen L, et al. JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells. BMC Cancer 2017; 17: 1–10.

Burlaka AP, Ganusevich II, Holotiuk VV, et al. Association between superoxide and NO generating activity of neutrophils and clinical characteristics of rectal cancer patients and its effect on the remote outcomes of combined treatment. Onkologiya 2016; 18: 294–9 (in Ukrainian).

Acquati F, Lualdi M, Bertilaccio S, et al. Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumourigenesis. Proc Natl Acad Sci 2013; 110: 8140–5.

Acquati F, Bertilaccio S, Grimaldi A et al. Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase. Proc Natl Acad Sci 2011; 108: 1104–9.

Casey G, Neville PJ, Plummer SJ, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32: 581–3.

Kladi-Skandali A, Mavridis K, Scorilas A, Sideris DC. Expressional profiling and clinical relevance of RNase κ in prostate cancer: a novel indicator of favorable progression-free survival. J Cancer Res Clin Oncol 2018; 144: 2049–57.

Vanli N, Sheng J, Li S, et al. Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer. Commun Biol 2022; 5: 625.




How to Cite

Burlaka А., Virko, S., Grygorenko, V., Samoylenko, O., Verbinenko, A., & Shlyakhovenko, V. (2023). THE CHANGES OF NO LEVEL AND RNase ACTIVITY IN TUMOR TISSUE ACCOMPANYING THE PROGRESSION OF PROSTATE CANCER. Experimental Oncology, 44(2), 159–162.



Short communications

Most read articles by the same author(s)